ライフサイエンスコーパス: viremic

1 en aged <10 years hospitalized with CAP were viremic.

2 nd in horses worldwide with approximately 3% viremic.

3 gan transplantation from a donor who was HCV viremic.

4 subsequent RNA testing revealed that 3 were viremic.

5 eir HIV infection and 2,816 (69.5%) were HIV viremic.

6 ere infected with HCV and 4,728 (81.8%) were viremic.

7 sk needlestick injury but nonetheless became viremic 11 weeks later.

8 ate treatment failure, and 1 was transiently viremic 17 months after treatment.

9 oscleral rims from 4 patients: 1 patient was viremic, 2 were viremic and IgM positive, and 1 was IgM

10 all anti-HCV-positive cases), 175 (61%) were viremic (3.8% overall prevalence in cohort), which was 5

11 re unaware of their status and those who are viremic across 26 Indian cities at various epidemic stag

12 All infected horses became viremic after 1 or 2 wk and viremia could be detected in

13 The main group of 346 lead-in nonresponders (viremic after 24 weeks of peginterferon-ribavirin therap

14 9 on ADV-TDF), and for patients who remained viremic after the addition of FTC (7/20 on TDF and 5/14

15 pressed and ARR, 1.38; 95% CI, 1.13-1.68 for viremic) among HIV-infected participants.

16 was evaluated in B cells from HIV-1-infected viremic and aviremic subjects and healthy subjects, in c

17 e I interferon (IFN) receptor (IFNAR) became viremic and died of infection after a high-dose vaginal

18 subjects who were HCV seronegative, both HCV viremic and HCV aviremic individuals were at increased r

19 om 4 patients: 1 patient was viremic, 2 were viremic and IgM positive, and 1 was IgM positive.

20 .9%) had anti-HCV antibodies, 54 (2.1%) were viremic and of those, 52 (2.1%) agreed to IL28B testing.

21 Twenty-four patients (7.6%) became viremic and three patients (1%) developed polyoma virus

22 pecimens from 12 donors who were or were not viremic and were or were not seropositive were investiga

23 Twelve apparently uninfected donors were viremic and/or positive for immunoglobulin M (IgM) and/o

24 h chronic HBV infection (118 aviremic and 67 viremic) and compared them with pDCs from uninfected ind

25 A total of 52 602 HCV seronegative, 9508 HCV viremic, and 913 HCV aviremic subjects were included.

26 l, 57 of 570 (10%) RV-positive patients were viremic, and all were children aged <10 years (n = 57/37

27 udies--Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (M

28 Among 171 viremic ART-experienced participants, NNRTI mutation pre

29 evels of plasma IFN-alpha/beta were found in viremic ART-treated and control subjects.

30 , SVR was achieved but the participants were viremic at later follow-up: 2 were reinfected with diffe

31 virus (HCV) recurrence in recipients who are viremic at time of liver transplantation (LT) is univers

32 infection recurs in liver recipients who are viremic at transplantation.

33 For patients who are still viremic at week 4, treatment durations even longer than

34 ent disease is universal in patients who are viremic before transplantation.

35 s) and those with mild (virurics) or severe (viremics) BKPyV reactivation after graft receipt.

36 PBMC from 69 aviremic and 56 viremic blood donors were then analyzed for the presence

37 ing West Nile virus (WNV) infection, acutely viremic blood donors, identified by nucleic acid amplifi

38 tion can be assessed by follow-up studies of viremic blood donors.

39 o DENV infection when fed on patient-derived viremic blood meals.

40 Nine patients and 1 healthy volunteer were viremic but had seronegative test results for JCV antibo

41 es were detected in 13 (92.86%) of 14 HPgV-2-viremic cases, and NS4AB antibodies were detected in 8 (

42 most with similar inflammatory infiltrate to viremic cases.

43 hildren (P = .002) and in the 3 seronegative viremic children (P = .025).

44 Dengue transmission risk was high near viremic children in both high- and low-incidence years.

45 Compared with the 5 seropositive viremic children, the median number of HCV-specific spot

46 4 expression was increased on B cells of HIV-viremic compared with HIV-aviremic and HIV-negative indi

47 iring various aspects of NK cell function in viremic condition, and several viral factors contribute

48 ting expression of one bNAb produced durable viremic control after ART was terminated.

49 nts by only several days and did not lead to viremic control after treatment interruption (clinical t

50 tudy to determine the safety and duration of viremic control after treatment interruption.

51 lood pressure control, lipid management) and viremic control among all people living with HIV to redu

52 lood pressure control, lipid management) and viremic control among people living with HIV regardless

53 inued emphasis by HIV care providers on both viremic control and preventive measures including smokin

54 y potent bNAbs not only resulted in complete viremic control but also led to a reduction in cell-asso

55 n of ART and immunotherapy enabled prolonged viremic control by a single bNAb after ART was withdrawn

56 s in HIV-1YU-2-infected humanized mice, with viremic control exhibited when a third antibody, 10-1074

57 significantly more strongly associated with viremic control than HLA-B*14:01.

58 rval [CI], 58-93 days), and the mean rate of viremic control was -0.66 log(10) VL per month.

59 viduals with protective HLA class I alleles, viremic control was associated with broad CD8(+) T cells

60 hypertension control, lipid management) and viremic control.

61 Within elite and viremic controller groups, those with protective class I

62 of a patient with progressive disease and a viremic controller.

63 sequence diversity analysis in the plasma of viremic controllers (<50-2000 copies RNA/mL).

64 HIV +Elite and Viremic controllers (EC/VCs) are able to control virus i

65 95% confidence interval {CI}, 0.35%-0.80%]), viremic controllers (ie, subjects with plasma HIV RNA le

66 rs (n = 16; viral load [VL], <75 copies/ml), viremic controllers (n = 14; VL, 75 to 2,000 copies/ml),

67 nd Pol peptides was highest in the elite and viremic controllers (P < 0.0001).

68 Viremic controllers and elite controllers/suppressors ma

69 These data suggest that some viremic controllers and elite suppressors are infected w

70 HLA-B*57 compared to twenty-three percent of viremic controllers and nine percent of noncontrollers (

71 In viremic controllers and progressors, we found variant re

72 Viremic controllers showed significantly broader mucosal

73 we show that CD8(+) T cells from 2 out of 4 viremic controllers were capable of effectively eliminat

74 In contrast, viremic controllers without protective HLA class I allel

75 64), those with levels of 50-2000 copies/mL (viremic controllers, n = 60); we also examined HIV-speci

76 For elite and viremic controllers, spontaneous virologic control was e

77 iduals receiving antiretroviral therapy, and viremic controllers.

78 d more-stable CD4 cell trends, compared with viremic controllers.

79 detectable viremia; 30 elite controllers; 30 viremic controllers; and 30 HIV-uninfected controls.

80 elite controllers (HIV-RNA < 75 copies/ml), "viremic" controllers (low-level viremia without therapy)

81 underwent kidney transplantation from an HCV-viremic deceased donor (median kidney donor profile inde

82 background), when directly blood-fed on 141 viremic dengue patients, have lower dengue virus (DENV)

83 cted subjects who were HCV seronegative, HCV viremic (detectable HCV RNA), or HCV aviremic (HCV serop

84 yield data and vice versa, and suggest that viremic donations will be rare relative to clinical dise

85 AA era has seen increased utilization of HCV-viremic donor livers, including HCV-viremic livers into

86 We assumed 4.9% HCV-viremic donor prevalence.

87 and transplantation of a kidney from an HCV-viremic donor was 6.3 weeks.

88 tion and graft survival in recipients of HCV-viremic donors (HCV-RNA positive as measured by nucleic

89 s with a concomitant increase in younger HCV viremic donors after brain death being identified.

90 total of 84% of the specimens obtained from viremic donors before IgM/IgG seroconversion demonstrate

91 Specimens from 102 viremic donors with and without WNV antibodies were used

92 The 13 viremic donors with no detectable PBMC-associated HCV RN

93 ially so in memory B cells from HIV-positive viremic donors, suggesting a possible underlying mechani

94 he majority of kidneys transplanted from HCV-viremic donors.

95 -positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P= .003)

96 samples or necropsy tissue samples from six viremic elephants.

97 36M was identified subsequent to a wild-type viremic episode.

98 000 copies/mL) and minor (50-1000 copies/mL) viremic episodes (VEs) and factors associated with major

99 tic interventions were performed in 59.1% of viremic episodes.

100 by 6 replicate TMA tests; samples that were viremic for >40 days were tested for WNV-neutralizing ac

101 Non-pregnant and pregnant animals remain viremic for 21 days and for up to at least 57 days, resp

102 Of the 182 cases investigated, 63% were viremic for the B19 virus.

103 carefully selected patients, the use of HCV-viremic grafts in the DAA era appears to be efficacious

104 dneys, with the KDPI again higher in the HCV-viremic group (56.8% versus 35.2%).

105 = 0.003) were significantly elevated in the viremic group, but crossed 1 at 21 and 24 months, respec

106 ts at baseline, and any patient who remained viremic (HBV DNA 400 copies/mL [69 IU/mL]) at week 288 o

107 ription polymerase chain reaction to confirm viremic HCV (V-HCV) infection.

108 The prevalence of viremic HCV has decreased in recent years among US born

109 ith a cohort of post-OLT and nontransplanted viremic HCV patients, the index patient with HCV clearan

110 Viremic HCV prevalence decreased from 1.32% in 1999-2004

111 s also created a rationale for utilizing HCV-viremic (HCV-RNA-positive) donors, including into HCV-ne

112 V-) to those of HCV+ nonviremic (HCV-NV) and viremic (HCV-V) hearts nationally and by UNOS region.

113 Outcomes following hepatitis C virus (HCV)-viremic heart transplantation into HCV-negative recipien

114 Willingness to accept HCV-viremic hearts for transplantation into HCV-negative rec

115 ortality and costs among those receiving HCV-viremic hearts were not >7% higher compared to HCV-negat

116 Patients receiving HCV-viremic hearts were treated, assuming $39 600/treatment

117 ipients willing and unwilling to receive HCV-viremic hearts.

118 tial negative consequences of receipt of HCV-viremic hearts.

119 Elite and viremic HIV controllers are able to control their HIV in

120 dependent, and this activity was impaired in viremic HIV infection but not in HCV infection.

121 s closely associated with killer activity in viremic HIV infection but not in healthy controls.

122 irect IFN-alpha stimulation was defective in viremic HIV infection, and this defect was not attributa

123 endent on PDC and NK cells) were impaired in viremic HIV infection.

124 ated inversely with plasma HIV RNA levels in viremic HIV patients.

125 miniscent of that described in patients with viremic HIV was detected.

126 ) expression was seen in CD4(+) T cells from viremic HIV(+) subjects compared to controls or followin

127 ood ILCs were severely depleted during acute viremic HIV-1 infection and that ILC numbers did not rec

128 ed gene expression in low- versus high-level viremic HIV-1 patients, suggesting a shift in apoptosis

129 on was highly increased in DCs isolated from viremic HIV-1 patients, suggesting that CD8(+) T cells a

130 nal cost a substantial number of unaware and viremic HIV-infected and HCV-infected individuals who we

131 l CD56(dim) NK cells increased in cART-naive viremic HIV-infected individuals (median [interquartile

132 cts in signaling were observed in cells from viremic HIV-infected persons and were especially pronoun

133 e populations are significantly increased in viremic HIV-infected subjects as compared with healthy s

134 ory CD4 T cells isolated from lymph nodes of viremic HIV-infected subjects.

135 he unlikely event that a mosquito fed upon a viremic host.

136 In contrast, 19 (90%) of 21 viremic IDUs displayed neutralizing antibodies (nAbs), c

137 Only 1 of 18 healthy volunteers were viremic in CD34+ cells and none in CD19+ cells.

138 ss, but found a substantial population to be viremic, in need of ART, and at risk for transmission.

139 ents were viruric and 28 (54%) patients were viremic, including 13 with biopsy-confirmed BKVAN.

140 ntibodies to E2 were detected in most HPgV-2-viremic individuals (92.86%), as is observed among indiv

141 an immunodeficiency virus (HIV)-infected and viremic individuals exhibit elevated levels of plasma cy

142 all fraction of plasmablasts in the blood of viremic individuals is HIV specific.

143 minant of the rate of disease progression in viremic individuals is unknown.

144 The detection rate of HIV viremic individuals was positively associated with under

145 ion in the absence of HCV viremia, while HCV-viremic individuals who previously were PWID continue to

146 a of HIV-infected individuals, especially in viremic individuals, and correlated with serum immunoglo

147 in levels were also elevated in HIV-infected viremic individuals, especially IgG, and correlated with

148 mber in the peripheral blood of HIV-infected viremic individuals, in whom they are associated with B-

149 lute CD4(+) T cell loss is more common among viremic individuals, suggesting that even very low-level

150 When Tregs are depleted from PBMCs of viremic individuals, the effect of the IL-10 signaling b

151 f 3BNC117 affects host antibody responses in viremic individuals.

152 are maintained at abnormally high levels in viremic individuals.

153 tion of CD4 T helper cells are restricted to viremic individuals.

154 lar B cell subpopulation in the blood of HIV-viremic individuals.

155 HIV-exposed, HCMV-viremic infants were more commonly referred for hospital

156 Viremic infection was common among serologically confirm

157 characterized HIV-specific CD4(+) T cells in viremic infection.

158 Ambulatory children with mild febrile viremic infections could represent an important componen

159 The probability of HCV-viremic kidney discard has declined over time.

160 tates registry data to examine trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019.

161 ity scores underestimated the quality of HCV-viremic kidneys based on 1-year allograft function.

162 ty and efficacy of transplantation of 30 HCV-viremic kidneys into HCV-negative recipients, followed b

163 demonstrated the safety of transplanting HCV-viremic kidneys into HCV-seronegative recipients.

164 lanted into HCV-seronegative recipients, HCV-viremic kidneys matched to HCV-non-viremic kidneys on pr

165 ents, HCV-viremic kidneys matched to HCV-non-viremic kidneys on predictors of organ quality, except H

166 o HCV-seropositive recipients, while 105 HCV-viremic kidneys were discarded.

167 During the first quarter of 2019, 200 HCV-viremic kidneys were transplanted into HCV-seronegative

168 m(2), P=0.056) after transplantation of HCV-viremic kidneys.

169 nor profile index scores assigned to the HCV-viremic kidneys.

170 orse short-term allograft function using HCV-viremic kidneys.

171 cipients received a rising proportion of HCV-viremic kidneys.

172 mononuclear cells from healthy controls and viremic KTR were stimulated using BK virus peptide libra

173 ol to generate BK-specific T cell lines from viremic KTR.

174 T cell lines can be reliably generated from viremic KTR.

175 To date, experience with the use of HCV viremic liver and kidney allografts in HCV-negative reci

176 ata on recipient and donor selection for HCV viremic liver and kidney allografts.

177 ally to recipient and donor selection of HCV viremic liver and kidney allografts.

178 growing interest in exploring the use of HCV viremic liver and kidney donor allografts in HCV-negativ

179 n of HCV-viremic donor livers, including HCV-viremic livers into HCV-negative recipients.

180 RL monotherapy withdrawal in non-immune, non-viremic LTR > 3 years post-LT.

181 w and detect Zika virus from the plasma of a viremic macaque.

182 Accordingly, low-viremic macaques had a higher frequency of both bone mar

183 nfected humans, we examined the plasma of 13 viremic macaques infected with SHIVSF162P3Nand 85 HIV-1-

184 lymphoid tissues and reproductive organs of viremic monkeys.

185 reases of CD8(+) Tregs with increasing VL in viremic monkeys.

186 cination, oral antiviral therapies in highly viremic mothers can further decrease MTCT of HBV.

187 Treatment with TDF for highly viremic mothers decreased infant HBV DNA at birth and in

188 patitis B virus (HBV) transmission in highly viremic mothers remains a global health issue.

189 LdT and LAM use in late pregnancy for highly viremic mothers was equally effective in reducing MTCT.

190 rentiated subjects with chronic HIV viremia (viremic noncontrollers [VNC]) from individuals with unde

191 Subjects were viremic on combination antiretroviral therapy (cART).

192 ive at time of donation, but was found to be viremic on retrospective testing.

193 ion on antiretroviral therapy, but not among viremic or untreated HIV-infected women.

194 t the time of transplant and received an HCV-viremic organ.

195 suppression after transplantation, these HCV-viremic organs are now being offered to transplant candi

196 Hepatitis C virus (HCV)-viremic organs are underutilized, and there is limited r

197 Strategies for HCV treatment with HCV-viremic organs have included delayed and preemptive appr

198 These results support utilization of HCV-viremic organs in selected recipients both with and with

199 rld experience of the transplantation of HCV-viremic organs into recipients who are aviremic.

200 ted data exist on the transplantation of HCV-viremic organs into recipients who are HCV negative.

201 ed by protocol on the transplantation of HCV-viremic organs.

202 Viremic participants had elevated liver enzyme levels an

203 sing M-CSF and GM-CSF, which is increased in viremic patient's plasma.

204 ducted a cross-sectional study of cART-naive viremic patients (ART(-)), virologically suppressed pati

205 Per protocol, viremic patients (HBV DNA level >/= 400 copies/mL or 69

206 C samples showed little variation for either viremic patients (median fold differences of 0.80 and 0.

207 heral blood mononuclear cells (PBMCs) from 5 viremic patients and 20 patients receiving effective ART

208 n by first analyzing monocytes isolated from viremic patients and patients undergoing antiretroviral

209 s, we cloned full-length Envs from plasma of viremic patients and tested their apoptosis-inducing pot

210 tible as or more susceptible than cells from viremic patients and uninfected donors to HIV-1 entry an

211 formed at the baseline for all patients, for viremic patients at week 144 or at the last time when th

212 IFN-alpha in response to HIV than pDCs from viremic patients but similar levels to pDCs from healthy

213 6(+) intermediate monocytes were elevated in viremic patients compared to those in uninfected control

214 In contrast, pDCs from viremic patients expressed membrane TRAIL without any st

215 Viremic patients had fewer codetected pathogens and were

216 At 12 months, all viremic patients had multiple resistance and compensator

217 In a subset of high viremic patients harboring R5 tropic HIV, there was a st

218 ivation, the low CD4 expression by pDCs from viremic patients may explain the weak IFN-alpha response

219 Blood mononuclear cells from viremic patients produced more TNFalpha in response to L

220 Characteristics of Vgamma2Vdelta2 T cells in viremic patients reflect both active responses (increasi

221 ly after transplantation, the liver graft of viremic patients universally becomes infected by circula

222 232 direct blood-feeding experiments on 118 viremic patients with dengue in Vietnam.

223 TLR9-L-activated pDCs from viremic patients with HBV did not induce cytolytic activ

224 by incubating control pDCs with plasma from viremic patients with HBV.

225 st of canonical Wnt signaling, was higher in viremic patients with lower CD4 counts.

226 f hepatitis B virus (HBV) e antigen-positive viremic patients with normal liver function and the inco

227 on was upregulated in HIV controllers versus viremic patients, and in vitro depletion of Wnt2b and/or

228 r isolation from the peripheral blood of ES, viremic patients, and uninfected donors.

229 infection: primary HIV infection, long-term viremic patients, aviremic patients treated with highly

230 amma2Vdelta2 T cells were more pronounced in viremic patients, compared with antiretroviral therapy r

231 In asymptomatic viremic patients, the highest pp65emia and qPCR values w

232 D4RTE percentage (77% vs 81%; P = .003) than viremic patients.

233 ation in these, with higher ADCC observed in viremic patients.

234 emia and CD4 T-cell depletion in contrast to viremic patients.

235 only five centers would transplant actively viremic patients.

236 CD4 counts and CD4:CD8 ratio specifically in viremic patients.

237 D4 and CD8 T cells were measured in 32 of 36 viremic pediatric kidney recipients using intracellular

238 Because DENV viremic people without clinical symptoms may be exposed

239 IV-1 latency, reservoir stability, low-level viremic persistence, and emergence of intermittent viral

240 The CVD mortality rate was highest among viremic persons (adjusted rate ratio [RR], 3.53 [95% con

241 on, at which point they increased during the viremic phase and approached pretransplant levels 3 mont

242 responses that are critical during the early viremic phase of CMV infection.

243 V) genotype C is associated with a prolonged viremic phase, delayed hepatitis B e antigen (HBeAg) ser

244 severe disease progression during the acute viremic phase, they cleared the virus faster and did not

245 atment of acute viral myocarditis during the viremic phase.

246 potential harms from steroid use during the viremic phase.

247 ellular target for ZIKV infection during the viremic phase.

248 egulation or hypoferremia during the primary viremic phases of HCV or HBV infection; serum iron margi

249 tion of individual library HCVpp by the last viremic plasma sample obtained before clearance was comp

250 Less than half of the viremic population was aware of having HCV infection.

251 lemented, there is a need to identify acute (viremic preseroconversion) infections and to discriminat

252 HCV viremic prevalence declined from 82% (95% CI, 78-86%) in

253 HCV viremic prevalence declined from 82% (95%CI 78%, 86%) in

254 HCV viremic prevalence peaked in 1994 at 3.3 (2.8-4.0) milli

255 studied the integration profile of HIV-1 in viremic progressors, individuals receiving antiretrovira

256 envelopes derived from chronically infected viremic progressors.

257 HCV-viremic PWID have elevated levels of immune activation w

258 (Eomes) differentiated LTR controllers from viremic relapsers and reciprocally correlated with granz

259 on differentiated LTR controllers from early viremic relapsers, correlating with granzyme B loading a

260 opensity-matched cohort of recipients of HCV-viremic (RNA positive) versus HCV-naive kidneys.

261 Three of 10 viremic samples amplified inefficiently with gSCA compar

262 P and qRT-PCR assays in detecting the dengue viremic samples.

263 ive seronegative children and 5 seropositive viremic siblings had functionally viable PBMCs.

264 When infused into viremic simian HIV (SHIV)-infected rhesus macaques, ther

265 um of outcomes, including rapid progression, viremic slow progression, and elite control.

266 rld experience on the transplantation of HCV-viremic solid organs into recipients who are HCV negativ

267 is activity, HBeAg seroconversion, and a low viremic state earlier than those carrying wild-type HBV.

268 nrolled adults with HIV/HCV, irrespective of viremic status, from 14 primary and tertiary clinics in

269 led HIV/HCV positive adults, irrespective of viremic status, from 14 primary and tertiary clinics in

270 re compared between controllers (n = 33) and viremic subjects (n = 27) using overlapping peptides, ma

271 -7 signaling in cells from both HIV-infected viremic subjects and healthy control subjects.

272 , and decreased levels of BTLA expression in viremic subjects compared to aviremic subjects and healt

273 gous plasma viral sequences from both EC and viremic subjects frequently harbored the typical cytotox

274 GBV-C-viremic subjects had significantly reduced CD4(+) and CD

275 s-clade neutralizing activity in plasma from viremic subjects were also assessed.

276 Compared with HCV seronegative subjects, HCV viremic subjects were at increased risk for stage 3 CKD

277 0 B57/B*5801-positive subjects (23 EC and 27 viremic subjects).

278 In viremic subjects, combined PD-L1/IL-10Ralpha blockade re

279 Within viremic subjects, the total IgG level correlated directl

280 uses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral

281 (-/-) mice infected with LCMV Cl 13 remained viremic throughout life from defects in the adaptive ant

282 ce as well as the relationship of disease to viremic titer remain unclear due to wide variation in st

283 At the same time, a decrease in HCV viremic transplant candidates has led to a growing inter

284 In 15 viremic, untreated patients, compared with 8 treated, vi

285 In contrast, highly viremic, unvaccinated controls did not develop detectabl

286 ruses a concern exists, that spillovers from viremic vaccinees could result in introduction of geneti

287 ents each in the cohort of recipients of HCV-viremic versus HCV-naive kidneys, with the KDPI again hi

288 .1) million noninstitutionalized people were viremic, which dropped to 1.9 (95% CI, 1.4-2.6) million

289 ble PVLs (<150 copies/mL), and 77 (72%) were viremic with a median PVL of 5450 copies/mL (interquarti

290 pproximately 1.90 million US adults remained viremic with HCV, and 0.33 million were at higher risk f

291 61 of the samples (46.9%) were classified as viremic with qRT-PCR.

292 th HCV-seronegative participants and (2) HCV-viremic with successfully treated nonviremic patients.

293 Animals became viremic within 4 days and succumbed to infection between

294 >60% decreased risk of AIDS for HCV-positive viremic women and HCV-negative women.

295 HCV-positive viremic women had a statistically significantly higher p

296 The AIDS risk was greater among HCV-positive viremic women in the highest tertile compared with the l

297 ned for anti-HCV antibodies and HCV RNA, and viremic women were tested for quantitative HCV RNA at 3,

298 n with HIV coinfection, and 407 HCV-positive viremic women with HIV coinfection (median follow-up tim

299 HCV-positive viremic women with HIV coinfection who have high levels

300 r children born to HCV antibody-positive and viremic women, aged >/=18 months, separately by maternal